To the Editor,

Current evidence suggest COVID-19 consequences are more severe in cancer patients who have a weakened immune system.[@bib1] Cancer care delivery should remain robust in view of potential disease progression if diagnosis and treatment are delayed.[@bib2] We describe herein key strategies in the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT) at the National Cancer Centre Singapore (NCCS) to provide effective care for patients with complex oncological conditions.

1. Key strategies to facilitate efficient cancer care and surgery {#sec1}
=================================================================

1.1. Team segregation ensuring care continuity {#sec1.1}
----------------------------------------------

Surgeons, both surgical oncologists and general surgeons, often work closely to ensure effective care for their patients. Due to COVID-19 however, many have been asked to form independent teams. Similarly, our surgical oncologists led independent teams where cross-team physical contact was prohibited, thus ensuring service continuity by preventing the quarantine of the entire team if an individual tests positive for COVID-19. Due to the requirement of multi-visceral resections needed for cytoreductive surgery, our team is proficient in the independent management of various oncological conditions.

1.2. Decreasing outpatient load and deferring non-urgent cases to ensure sustainability {#sec1.2}
---------------------------------------------------------------------------------------

In the outpatient setting, significant effort was devoted to review patient lists for clinic sessions and to defer non-urgent appointments. New referrals assessed with a high likelihood of cancer would undergo diagnostic imaging and biopsy on the same day, where possible, to minimize clinic visits.

1.3. Efficacious manpower deployment to maintain efficiency {#sec1.3}
-----------------------------------------------------------

Under institutional guidelines, malignant cases, suspicious or high-risk cases of malignancy, and surgical emergencies were allowed to proceed while other surgeries were postponed. Furthermore, during this pandemic, surgical emergencies were diverted to the acute surgical team, allowing efficient deployment of manpower within the SPRinT team to maintain a high patient load.

2. Our Results {#sec2}
==============

We demonstrate herein positive results showing no compromise in the timing of cancer care delivery and patient outcomes following implementation of our surgical unit's key strategies ([Table 1](#tbl1){ref-type="table"} ). Fewer diagnostic and benign cases (table codes 1--4, [Supplementary Table S1](#appsec1){ref-type="sec"}) while more complex surgeries were performed (table codes 5--7, [Supplementary Table S1](#appsec1){ref-type="sec"}). Although median operating duration was longer in 2020, partially contributed by the turnover time and recovery of patients with the anesthetic team, surgical caseload was similar in both years. Furthermore, complication rates (Clavien-Dindo grade 3 and above) between 2020 and 2019 were similar at 2.1% and 2.2%, respectively.Table 1Comparison of surgical cases treated by our surgical oncology unit in 2019 and 2020.Table 1Time period7 Feb to 15 May 20207 Feb to 15 May 2019**Number of cases handled by 1 surgical oncologist**89 (91.8%)75 (80.6%)**Number of cases handled by ≥2 surgical oncologists operating together**8 (8.2%)18 (19.4%)**Number of benign cases (%)**7 (7.2%)21 (22.6%)Acute surgical emergency (%)2 (2.1%)Symptomatic (%)2 (2.1%)Underlying malignancy and surgery required to continue adjuvant therapy (%)3 (3.0%)**Number of suspicious/malignant cases (%)**90 (92.8%)72 (77.4%)**Number of operations (%)**Tables 1 and 2 [a](#tbl1fna){ref-type="table-fn"}13 (13.4%)22 (23.7%)Tables 3 and 4 [a](#tbl1fna){ref-type="table-fn"}36 (37.1%)41 (44.1%)Tables 5 and 6 [a](#tbl1fna){ref-type="table-fn"}35 (36.1%)18 (19.3%)Table 7 [a](#tbl1fna){ref-type="table-fn"}13 (13.4%)12 (12.9%)**Median duration of operation (min)**Tables 1 and 2 [a](#tbl1fna){ref-type="table-fn"}70.025.0Tables 3 and 4 [a](#tbl1fna){ref-type="table-fn"}132.590.0Tables 5 and 6 [a](#tbl1fna){ref-type="table-fn"}195.0192.5Table 7 [a](#tbl1fna){ref-type="table-fn"}460.0372.5**New outpatient caseload**91122**Follow-up outpatient caseload**580813**Maximum duration of waiting time for new referral to be seen in clinic (days)**3.7 (5--6)16.3 (12--13)[^3]

With a deferment in non-urgent cases, an overall decrease in patient numbers were seen in clinic ([Table 1](#tbl1){ref-type="table"}). Similarly, follow-up cases was fewer in 2020 at 580 compared to 813 in 2019. Notably, mean maximum duration of waiting time for a new referral to be seen in clinic was shorter in 2020 compared to 2019 at 3.7 (range: 5--6) and 16.3 (range: 12--13) days, respectively.

Despite the challenges presented during the COVID-19 pandemic, our surgical oncology subspecialty unit provided timely oncological surgery and care without compromising patient outcomes. In countries recovering from the pandemic and ramping up cancer care, these strategies will provide a useful framework and are worth considering.
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